Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
Status:
Completed
Trial end date:
2012-12-10
Target enrollment:
Participant gender:
Summary
This phase I/II trial is studying the side effects and best dose of sorafenib in treating
young patients with relapsed or refractory solid tumors or leukemia. Sorafenib may stop the
growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking
blood flow to the cancer.